FOLLOW US

In a groundbreaking development, Eli Lilly, a US-based pharmaceutical company, has released the final results of trials on donanemab, a revolutionary Alzheimer’s drug. It works as an infusion that aids the brain in clearing out sticky amyloid plaques impeding cell communication. 

This wonder drug has the potential to slow the progression of Alzheimer's disease by up to 60 percent, raising hopes that dementia could become as treatable as common conditions like diabetes or asthma.

Donanemab postpones the worsening of clinical symptoms and enables patients to maintain their daily activities for an extended period. Tasks such as shopping, housekeeping, managing finances, and taking medication become more manageable for those undergoing this treatment. 

 With over 6 million Americans living with Alzheimer's disease, the impact of these treatments on individuals' lives cannot be overstated. In the UK, an estimated 944,000 people are living with dementia, with the majority affected by Alzheimer's.

Blood tests to identify the initial signs of Alzheimer's are in development. These tests are proposed for routine screenings for people above the age of 50. And it will help ensure that patients can receive the drug during the earliest stages of the disease.

Dr. Richard Oakley, the associate director of research and innovation at Alzheimer's Society, expresses his enthusiasm, stating, "This is truly a turning point in the fight against Alzheimer's."

Oakley believes that donanemab and similar treatments mark the initial steps towards a future where Alzheimer's can be managed as a long-term condition, allowing individuals to effectively handle their symptoms and lead fulfilled lives, much like those with diabetes or asthma.

Revolutionary Alzheimer's Drug

Eli Lilly has already submitted donanemab data to the US Food and Drug Administration (FDA). And submissions to other global regulators are underway, as well.

Donanemab's success follows another positive development in Alzheimer's treatment. Eisai/Biogen's lecanemab, which slows decline by 27 percent, has gained FDA approval in the US.

A recent study, published in the Journal of the American Medical Association (JAMA) and presented at the Alzheimer's Association International Conference (AAIC) in Amsterdam, reveals that the revolutionary Alzheimer’s drug, tested on 1,800 people, slows the disease by a minimum of 35 percent, making it the most effective dementia drug discovered thus far. 

For those in the earliest stages of Alzheimer's, donanemab reduces decline by an impressive 60 percent, with disease progression halted for at least a year in almost half of the trial participants.

According to Dr Liz Coulthard, associate professor in Dementia Neurology, at the University of Bristol,  “Alzheimer’s is a common condition, and we want people to be eligible for treatment on the basis of need, rather than access being limited to those who can afford private care or live in certain areas of the country.”

USA Herald, Alzheimer's drug, donanemab, dementia treatment, amyloid plaques, clinical symptoms, blood tests, early diagnosis, turning point, long-term condition, fulfilled lives, PET scanners, breakthrough, drug approval, FDA, MHRA, cost effectiveness, Alzheimer's statistics, disease progression, NHS overhaul, treatment eligibility, research study, JAMA, AAIC